The Goldman Sachs Group Cuts Gossamer Bio (NASDAQ:GOSS) Price Target to $7.00

Gossamer Bio (NASDAQ:GOSS) had its price target decreased by analysts at The Goldman Sachs Group from $8.00 to $7.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock.

Several other analysts also recently issued reports on GOSS. Wedbush reissued an “outperform” rating and issued a $4.00 price target on shares of Gossamer Bio in a research report on Friday, March 14th. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Gossamer Bio in a research report on Tuesday, March 18th.

Gossamer Bio Stock Up 1.1 %

Shares of NASDAQ GOSS traded up $0.01 during trading on Thursday, hitting $0.84. 432,876 shares of the company traded hands, compared to its average volume of 1,555,897. The company has a debt-to-equity ratio of 3.64, a quick ratio of 6.74 and a current ratio of 6.74. The business’s fifty day moving average is $1.16 and its 200 day moving average is $0.99. The firm has a market capitalization of $190.64 million, a price-to-earnings ratio of -2.62 and a beta of 1.88. Gossamer Bio has a fifty-two week low of $0.50 and a fifty-two week high of $1.55.

Gossamer Bio (NASDAQ:GOSS) last announced its quarterly earnings results on Tuesday, March 18th. The company reported ($0.15) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.15). The firm had revenue of $9.38 million during the quarter, compared to the consensus estimate of $7.02 million. Equities research analysts predict that Gossamer Bio will post -0.28 earnings per share for the current fiscal year.

Institutional Trading of Gossamer Bio

Institutional investors have recently made changes to their positions in the company. Charles Schwab Investment Management Inc. grew its position in Gossamer Bio by 1.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,241,979 shares of the company’s stock worth $1,123,000 after purchasing an additional 13,902 shares in the last quarter. Smith Moore & CO. grew its holdings in shares of Gossamer Bio by 32.7% in the fourth quarter. Smith Moore & CO. now owns 300,000 shares of the company’s stock valued at $271,000 after acquiring an additional 74,000 shares in the last quarter. Monaco Asset Management SAM increased its position in shares of Gossamer Bio by 39.5% during the fourth quarter. Monaco Asset Management SAM now owns 5,371,641 shares of the company’s stock valued at $4,859,000 after acquiring an additional 1,520,721 shares during the last quarter. Velan Capital Investment Management LP bought a new stake in Gossamer Bio during the fourth quarter worth $68,000. Finally, Graham Capital Management L.P. purchased a new position in Gossamer Bio in the fourth quarter worth $32,000. Institutional investors own 81.23% of the company’s stock.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.